NovaBay Pharmaceuticals, Inc. (formerly known as NovaCal Pharmaceuticals, Inc.) Appoints Gail Maderis, BayBio (Bay Area Bioscience Association) President and CEO and Former Genzyme Corporation Senior Executive, to Its Board of Directors

EMERYVILLE, Calif., Oct. 11, 2010 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical stage biotechnology company developing first-in-class, anti-infective compounds for the treatment and prevention of antibiotic-resistant infections, has appointed Gail Maderis to its Board of Directors. Ms. Maderis will replace Harry F. Hixson, Jr., Ph.D.

Back to news